UBS Group
AURA icon

UBS Group’s Aura Biosciences AURA Stock Holding History

UBS Group’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$492K Sell
69,230
-49,674
-42% -$355K ﹤0.01% 6240
2026
Q1 		$795K Sell
118,904
-52,735
-31% -$303K ﹤0.01% 5730
2025
Q4 		$935K Sell
171,639
-725,172
-81% -$4.31M ﹤0.01% 5636
2025
Q3 		$5.54M Buy
896,811
+5,783
+0.6% +$37.8K ﹤0.01% 3928
2025
Q2 		$5.58M Buy
891,028
+137,870
+18% +$806K ﹤0.01% 3762
2025
Q1 		$4.41M Buy
753,158
+65,836
+10% +$498K ﹤0.01% 3914
2024
Q4 		$5.65M Buy
687,322
+665,336
+3,026% +$6.26M ﹤0.01% 3692
2024
Q3 		$196K Buy
21,986
+7,721
+54% +$66.2K ﹤0.01% 5890
2024
Q2 		$108K Sell
14,265
-22,381
-61% -$164K ﹤0.01% 6123
2024
Q1 		$288K Buy
36,646
+5,584
+18% +$46.3K ﹤0.01% 5600
2023
Q4 		$275K Buy
31,062
+30,337
+4,184% +$257K ﹤0.01% 5563
2023
Q3 		$6.5K Buy
+725
New +$7.8K ﹤0.01% 7296
2023
Q2 		– Sell
-545
Closed -$5.06K – 8895
2023
Q1 		$5.06K Sell
545
-559
-51% -$5.81K ﹤0.01% 8090
2022
Q4 		$11.6K Sell
1,104
-11,163
-91% -$142K ﹤0.01% 8381
2022
Q3 		$222K Sell
12,267
-4,053
-25% -$61.3K ﹤0.01% 4996
2022
Q2 		$231K Buy
16,320
+15,566
+2,064% +$258K ﹤0.01% 4798
2022
Q1 		$17K Sell
754
-1,893
-72% -$36.1K ﹤0.01% 7633
2021
Q4 		$45K Buy
+2,647
New +$47.3K ﹤0.01% 6995

Other funds holding AURA

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

UBS Group's AURA Position: Q2 2026 in Review

UBS Group reduced its Aura Biosciences (AURA) stake by 42% in Q2 2026, selling an estimated $355K and leaving 69,230 shares worth $492K. The position accounts for ﹤0.01% of the portfolio, ranked #6240.

UBS Group first reported a position in AURA in Q4 2021 and has held it in 18 quarters since. The position peaked at $5.65M in Q4 2024. 146 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • UBS Group held 69,230 shares of Aura Biosciences worth $492K as of Q2 2026.
  • UBS Group sold 49,674 Aura Biosciences shares in Q2 2026, an estimated $355K.
  • Aura Biosciences made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6240 holding.
  • UBS Group first reported a position in Aura Biosciences in Q4 2021 and has held it in 18 quarters since.
  • UBS Group's Aura Biosciences position peaked at $5.65M in Q4 2024.
  • 146 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.